Viral peptide immunogens: Current challenges and opportunities

Journal of Peptide Science

Volumn 13, Issue 12, 2007, Pages 776-786

  Azizi, Ali ^a,b,c   Diaz Mitoma, Francisco ^a,b,c  

^a Variation Biotechnologies Inc   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Immune response; Peptide epitopes; Vaccine; Viral infection

Indexed keywords

AUTOANTIGEN; EPITOPE; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; SYNTHETIC PEPTIDE; VIRUS VACCINE;

ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; AUTOIMMUNITY; B LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; LETHALITY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENDAI VIRUS; T LYMPHOCYTE; VACCINATION; VIRUS INFECTION;

ANIMALS; EPITOPES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LYMPHOCYTES; PEPTIDES; VACCINES, SYNTHETIC; VIRAL PROTEINS;

MUS; SENDAI VIRUS;

EID: 37349026910     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.896     Document Type: Review

References (161)

1. Men Y, Audran R, Thomasin C, Eberl G, Demotz S, Merkle HP, Gander B, Corradin G. MHC class I- and class II-restricted processing and presentation of microencapsulated antigens. Vaccine 1999; 17: 1047-1056.
2. Goletz TJ, Klimpel KR, Arora N, Leppla SH, Keith JM, Berzofsky JA. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 12059-12064.
3. Maecker HT, Maino VC. T cell immunity to HIV: defining parameters of protection. Curr. HIV. Res. 2003; 1: 249-259.
4. Boles JW, Pitt ML, LeClaire RD, Gibbs PH, Torres E, Dyas B, Ulrich RG, Bavari S. Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. Clin. Immunol. 2003; 108: 51-59.
5. Celia H, Wilson-Kubalek E, Milligan RA, Teyton L. Structure and function of a membrane-bound murine MHC class I molecule. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 5634-5639.
6. Fruh K, Ahn K, Peterson PA. Inhibition of MHC class I antigen presentation by viral proteins. J. Mol. Med. 1997; 75: 18-27.
7. Ljunggren HG, Thorpe CJ. Principles of MHC class I-mediated antigen presentation and T cell selection. Histol. Histopathol. 1996; 11: 267-274.
8. Jones RA, Scott CS, Child JA. Expression of MHC class I and class I-like gene products on the cell membrane of mature and immature T cells. Leuk. Res. 1988; 12: 799-804.
9. Daar AS, Fuggle SV, Fabre JV, Ting A, Morris PJ. The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation 1984; 38: 287-292.
10. Habermehl P, Lignitz A, Knuf M, Schmitt HJ, Slaoui M, Zepp F. Cellular immune response of a varicella vaccine following simultaneous DTaP and VZV vaccination. Vaccine 1999; 17: 669-674.
11. Arvin AM. Immune responses to varicella-zoster virus, Infect. Dis. Clin. North Am. 1996; 10: 529-570.
12. Ovsyannikova IG, Dhiman N, Jacobson RM, Vierkant RA, Poland GA. Frequency of measles virus-specific CD4+ and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine. Clin. Diagn. Lab Immunol. 2003; 10:411-416.
13. Jung MC, Diepolder HM, Pape GR. T cell recognition of hepatitis B and C viral antigens. Eur. J. Clin. Invest. 1994; 24: 641-650.
14. Takahashi H. Antigen presentation in vaccine development. Comp Immunol. Microbiol. Infect. Dis. 2003; 26: 309-328.
15. Lu NQ. A speculative view of immune recognition. Immunol. Invest. 1994; 23: 53-71.
16. Van Kaer L, Ashton-Rickardt PG, Eichelberger M, Gaczynska M, Nagashima K, Rock KL, Goldberg AL, Doherty PC, Tonegawa S. Altered peptidase and viral-specific T cell response in LMP2 mutant mice. Immunity 1994; l: 533-541.
17. Toes RE, Nussbaum AK, Degermann S, Schirle M, Emmerich NP, Kraft M, Laplace C, Zwinderman A, Dick TP, Muller J, Schonfisch B, Schmid C, Fehling HJ, Stevanovic S, Rammensee HG, Schild H. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J. Exp. Med. 2001; 194: 1-12.
18. York IA, Goldberg AL, Mo XY, Rock KL. Proteolysis and class I major histocompatibility complex antigen presentation, Immunol. Rev. 1999; 172: 49-66.
19. Mo XY, Cascio P, Lemerise K, Goldberg AL, Rock K. Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides. J. Immunol. 1999; 163: 5851-5859.
20. Deng H, Fosdick L, Sercarz E. The involvement of antigen processing in determinant selection by class II MHC and its relationship to immunodominance. APMIS 1993; 101: 655-662.
21. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 1999; 17: 51-88.
22. Schaeffer EB, Sette A, Johnson DL, Bekoff MC, Smith JA, Grey HM, Buus S. Relative contribution of "determinant selection" and "holes in the T-cell repertoire" to T-cell responses. Proc. Natl. Acad. Sci. U.S.A. 1989; 86: 4649-4653.
23. Chen W, Norbury CC, Cho Y, Yewdell JW, Bennink JR. Immunoproteasomes shape immunodominance hierarchies of antiviral CD8(+) T cells at the levels of T cell repertoire and presentation of viral antigens, J. Exp. Med. 2001; 193: 1319-1326.
24. Lauvau G, Kakimi K, Niedermann G, Ostankovitch M, Yotnda P, Firat H, Chisari FV, van Endert PM. Human transporters associated with antigen processing (TAPs) select epitope precursor peptides for processing in the endoplasmic reticulum and presentation to T cells, J. Exp. Med. 1999; 190: 1227-1240.
25. Bui HH, Peters B, Assarsson E, Mbawuike I, Sette A. Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc. Natl. Acad. Sci. U. S. A. 2007; 104: 246-251.
26. Parker KC, Shields M, DiBrino M, Brooks A, Coligan JE. Peptide binding to MHC class I molecules: implications for antigenic peptide prediction, Immunol. Res. 1995; 14: 34-57.
27. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains, J. Immunol. 1994; 152: 163-175.
28. Zhan X, Martin LN, Slobod KS, Coleclough C, Lockey TD, Brown SA, Stambas J, Bonsignori M, Sealy RE, Blanchard JL, Hurwitz JL. Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. Vaccine 2005; 23: 5306-5320.
29. Le Gal FA, Ayyoub M, Dutoit V, Widmer V, Jager E, Cerottini JC, Dietrich PY, Valmori D. Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CDS+ T-cell responses to the tumor-specific antigen NY-ESO-1. J. Immunother. 2005; 28: 252-257.
30. Vider-Shalit T, Raffaeli S, Louzoun Y. Virus-epitope vaccine design: informatic matching the HLA-I polymorphism to the virus genome. Mol. Immunol. 2007; 44: 1253-1261.
31. Lau M, Terasaki PI, Park MS. International cell exchange, 1994. Clin. Transpl. 1994; 467-488.
32. van Endert PM. Designing peptide vaccines for cellular cross-presentation. Biologicals 2001; 29: 285-288.
33. Martin W, Sbai H, De Groot AS. Bioinformatics tools for identifying class I-restricted epitopes. Methods 2003; 29: 289-298.
34. Culshaw S, Larosa K, Tolani H, Han X, Eastcott JW, Smith DJ, Taubman MA. Immunogenic and protective potential of mutans streptococcal glucosyltransferase peptide constructs selected by major histocompatibility complex class II allele binding. Infect. Immun. 2007; 75: 915-923.
35. De Groot AS, Bosma A, Chinai N, Frost J, Jesdale BM, Gonzalez MA, Martin W, Saint-Aubin C. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine 2001; 19: 4385-4395.
36. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296: 2354-2360.
37. Azizi A, Anderson DE, Ghorbani M, Gee K, Diaz-Mitoma F. Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters. BMC. Immunol.,2006; 7: 25.
38. Naas T, Ghorbani M, Alvarez-Maya I, Lapner M, Kothary R, De Repentigny Y, Gomes S, Babiuk L, Giulivi A, Soare C, Azizi A, Diaz-Mitoma F. Characterization of liver histopathology in a transgenic mouse model expressing genotype la hepatitis C virus core and envelope proteins 1 and 2. J. Gen. Virol. 2005; 86: 2185-2196.
39. Gao F. Robertson DL, Carruthers CD, Li Y, Bailes E, Kostrikis LG, Salminen MO, Bibollet-Ruche F, Peeters M, Ho DD, Shaw GM, Sharp PM, Hahn BH. An isolate of human immunodeficiency virus type 1 originally classified as subtype I represents a complex mosaic comprising three different group M subtypes (A, G, and I). J. Virol. 1998; 72: 10234-10241.
40. Arnon R, Ben Yedidia T. Old and new vaccine approaches. Int. Immunopharmacol. 2003; 3: 1195-1204.
41. Kawada M, Igarashi H, Takeda A, Tsukamoto T, Yamamoto H, Dohki S, Takiguchi M, Matano T. Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques. J. Virol. 2006; 80: 1949-1958.
42. Falo LD, Colarusso LJ, Benacerraf B, Rock KL Jr. Serum proteases alter the antigenicity of peptides presented by class I major histocompatibility complex molecules. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 8347-8350.
43. Amoscato AA, Prenovitz DA, Lotze MT. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J. Immunol. 1998; 161: 4023-4032.
44. Larsen SL, Pedersen LO, Buus S, Stryhn A. T cell responses affected by aminopeptidase N (CD13)-mediated trimming of major histocompatibility complex class II-bound peptides. J. Exp. Med. 1996; 184: 183-189.
45. Amacker M, Engler O, Kammer AR, Vadrucci S, Oberholzer D, Cerny A, Zurbriggen R. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int. Immunol. 2005; 17: 695-704.
46. Zeng W, Gauci S, Ghosh S, Walker J, Jackson DC. Characterisation of the antibody response to a totally synthetic immunocontraceptive peptide vaccine based on LHRH. Vaccine 2005; 23: 4427-4435.
47. Dei Giudice G. Vaccination strategies. An overview. Vaccine 2003; 21 (Suppl 2): S83-S88.
48. Esser MT, Marchese RD, Kierstead LS, Tussey LG, Wang F, Chirmule N, Washabaugh MW. Memory T cells and vaccines. Vaccine 2003; 21: 419-430.
49. Yang LT, Peng H, Zhu ZL, Li G, Huang ZT, Zhao ZX, Koup RA, Bailer RT, Wu CY. Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients. Clin. Immunol. 2006; 120: 171-178.
50. Jangpatarapongsa K, Sirichaisinthop J, Sattabongkot J, Cui L, Montgomery SM, Looareesuwan S, Troye-Blomberg M, Udomsangpetch R. Memory T cells protect against Plasmodium vivax infection. Microbes Infect. 2006: 8: 680-686.
51. Srivastava IK, Ulmer JB, Barnett SW. Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design. Expert Rev. Vaccines 2004; 3: S33-S52.
52. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC. Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. J. Virol. 2005; 79: 10108-10125.
53. Sarmati L, d'Ettorre G, Nicastri E, Ercoli L, Uccella I, Massetti P, Parisi SG, Vullo V, Andreoni M. Neutralizing antibodies against autologous human immunodeficiency virus Type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment. Clin. Diagn. Lab. Immunol. 2001; 8: 822-824.
54. Locher CP, Grant RM, Collisson EA, Reyes-Teran G, Elbeik T, Kahn JO, Levy JA. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination. AIDS Res. Hum. Retroviruses 1999; 15: 1685-1689.
55. Duerr A, Wasserheit JN, Corey L. HIV vaccines: new frontiers in vaccine development. Clin. Infect. Dis. 2006; 43: 500-511.
56. Luckay A, Sidhu MK, Kjeken R, Megati S, Chong SY, Roopchand V, Garcia-Hand D, Abdullah R, Braun R, Montefiori DC, Rosati M, Felber BK, Pavlakis GN, Mathiesen I, Israel ZR, Eldridge JH, Egan MA. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J. Virol. 2007; 81: 5257-5269.
57. Oliveira-Ferreira J, Daniel-Ribeiro C. Protective CD8+ T cell responses against the pre-erythrocytic stages of malaria parasites: an overview. Mem. Inst. Oswaldo Cruz 2001; 96: 221-227.
58. Blattman JN, Antia R, Sourdive DJ, Wang X, Kaech SM, Murali-Krishna K, Altman JD, Ahmed R. Estimating the precursor frequency of naive antigen-specific CD8 T cells. J. Exp. Med. 2002; 195: 657-664.
59. Bousso P, Wahn V, Douagi I, Horneff G, Pannetier C, Le Deist F, Zepp F, Niehues T, Kourilsky P, Fischer A, de Saint BG. Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 274-278.
60. Acierno PM, Schmitz JE, Gorgone DA, Sun Y, Santra S, Seaman MS, Newberg MH, Mascola JR, Nabel GJ, Panicali D, Letvin NL. Preservation of functional virus-specific memory CD8+ T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys. J. Immunol. 2006; 176: 5338-5345.
61. Haegele KF, Stueckle CA, Malin JP, Sindern E. Increase of CD8+ T-effector memory cells in peripheral blood of patients with relapsing-remitting multiple sclerosis compared to healthy controls. J. Neuroimmunol. 2007; 183: 168-174.
62. Kamath A, Woodworth JS, Behar SM. Antigen-specific CD8+ T cells and the development of central memory during Mycobacterium tuberculosis infection. J. Immunol. 2006; 177: 6361-6369.
63. Stock AT, Jones CM, Heath WR, Carbone FR. Cutting edge: central memory T cells do not show accelerated proliferation or tissue infiltration in response to localized herpes simplex virus-1 infection. J. Immunol. 2006; 177: 1411-1415.
64. Letsch A, Keilholz U, Kern F, Asemissen AM, Thiel E, Scheibenbogen C. Specific central memory T cells in the bone marrow of patients immunized against tyrosinase peptides. J. Immunother. 2006; 29: 201-207.
65. Levy JA. HIV pathogenesis: knowledge gained after two decades of research. Adv. Dent. Res. 2006; 19: 10-16.
66. Gallo RC. The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years. The Lancet 2005; 366: 1894-1898.
67. Girard MP, Osmanov SK, Kieny MP. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 2006; 24: 4062-4081.
68. Rowland-Jones SL, Dong T, Fowke KR, Kimani J, Krausa P, Newell H, Blanchard T, Ariyoshi K, Oyugi J, Ngugi E, Bwayo J, MacDonald KS, McMichael AJ, Plummer FA. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest 1998; 102: 1758-1765.
69. Jin X, Gao X, Ramanathan M, Deschenes GR, Nelson GW, O'Brien SJ, Goedert JJ, Ho DD, O'Brien TR, Carrington M Jr. Human immunodeficiency virus type 1 (HIV-1)-specific CDS+-T-cell responses for groups of HIV-1-infected individuals with different HLA-B*35 genotypes. J. Virol. 2002; 76: 12603-12610.
70. Monceaux V, Viollet L, Petit F, Ho Tsong FR, Cumont MC, Zaunders J, Hurtrel B, Estaquier J. CD8+ T cell dynamics during primary simian immunodeficiency virus infection in macaques: relationship of effector cell differentiation with the extent of viral replication. J. Immunol. 2005; 174: 6898-6908.
71. Kan-Mitchell J, Bisikirska B, Wong-Staal F, Schaubert KL, Bajcz M, Bereta M. The HIV-1 HLA-A2-SLYNTVATL is a help-independent CTL epitope. J. Immunol. 2004; 172: 5249-5261.
72. Jennes W, Sawadogo S, Koblavi-Deme S, Vuylsteke B, Maurice C, Roels TH, Chorba T, Nkengasong JN, Kestens L. Positive association between beta-chemokine-producing T cells and HIV type 1 viral load in HIV-infected subjects in Abidjan, Cote d'Ivoire. AIDS Res. Hum. Retroviruses 2002; 18: 171-177.
73. Nyambi PN, Mbah HA, Burda S, Williams C, Gorny MK, Nadas A, Zolla-Pazner S. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J. Virol. 2000: 74: 7096-7107.
74. Braibant M, Brunet S, Costagliola D, Rouzioux C, Agut H, Katinger H, Autran B, Barin F. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. AIDS 2006; 20: 1923-1930.
75. Kothe DL, Li Y, Decker JM, Bibollet-Ruche F, Zammit KP, Salazar MG, Chen Y, Weng Z, Weaver EA, Gao F, Haynes BF, Shaw GM, Korber BT, Hahn BH. Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 2006; 352: 438-449.
76. Gao F, Weaver EA, Lu Z, LiY, Liao HX, Ma B, Alam SM, Scearce RM, Sutherland LL, Yu JS, Decker JM, Shaw GM, Montefiori DC, Korber BT, Hahn BH, Haynes BF. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group in consensus envelope glycoprotein. J. Virol. 2005; 79: 1154-1163.
77. Yang OO, Sarkis PT, Ali A, Harlow JD, Brander C, Kalams SA, Walker BD. Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes. J. Exp. Med. 2003; 197: 1365-1375.
78. Friedrich TC, Watkins DI. The role of the SIV model in AIDS vaccine research. IAVI. Rep. 2005; 9: 6-1, 8.
79. Carlos MP, Anderson DE, Gardner MB, Torres JV. Immunogenicity of a vaccine preparation representing the variable regions of the HIV type 1 envelope glycoprotein. AIDS Res. Hum. Retroviruses 2000; 16: 153-161.
80. Nabel GJ. Immunology. Close to the edge: neutralizing the HIV-1 envelope. Science 2005; 308: 1878-1879.
81. Gomez CE, Abaitua F, Rodriguez D, Esteban M. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma. Virus Res. 2004; 105: 11-22.
82. Anderson DE, Carlos MP, Nguyen L, Torres JV. Overcoming original (antigenic) sin. Clin. Immunol. 2001; 101: 152-157.
83. Sijts AJ, Ossendorp F, Mengede EA, van den Elsen PJ, Melief CJ. Immunodominant mink cell focus-inducing murine leukemia virus (MuLV)-encoded CTL epitope, identified by its MHC class I-binding motif, explains MuLV-type specificity of MCF-directed cytotoxic T lymphocytes. J. Immunol. 1994; 152:106-116.
84. Li H, Natarajan K, Malchiodi EL, Margulies DH, Mariuzza RA. Three-dimensional structure of H-2Dd complexed with an immunodominant peptide from human immunodeficiency virus envelope glycoprotein 120. J. Mol. Biol. 1998; 283: 179-191.
85. Pahl-Seibert MF, Juelch M, Podlech J, Thomas D, Deegen P, Reddehase MJ, Holtappels R. Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting. J. Virol. 2005; 79: 5400-5413.
86. Cheuk E, D'Souza C, Hu N, Liu Y, Lang H, Chamberlain JW. Human MHC class I transgenic mice deficient for H2 class I expression facilitate identificatton and characterization of new HLA class I-restricted vital T cell epitopes. J. Immunol. 2002; 169: 5571-5580.
87. Velders MP, Weijzen S, Eiben GL, Elmishad AG, Kloetzel PM, Higgins T, Ciccarelli RB, Evans M, Man S, Smith L, Kast WM. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J. Immunol. 2001; 166: 5366-5373.
88. Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 2001; 19: 4652-4660.
89. Nierkens S, Aalbers M, Bol M, Bleumink R, van Kooten P, Boon L, Pieters R. Differential requirement for CD28/CTLA-4-CD80/CD86 interactions in drug-induced type I and type 2 immune responses to trinitrophenyl-ovalbumin. J. Immunol. 2005; 175: 3707-3714.
90. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995; 80: 707-718.
91. Bour-Jordan H, Blueston JA. CD28 function: a balance of costimulatory and regulatory signals. J. Clin. Immunol. 2002; 22: 1-7.
92. Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 1999; 59: 5800-5807.
93. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J. Immunol. 2006; 177: 7980-7989.
94. Zuckermann FA, Martin S, Husmann RJ, Brandt J. Use of interleukin 12 to enhance the cellular immune response of swine to an inactivated herpesvirus vaccine. Adv. Vet. Med. 1999; 41: 447-461.
95. Mapletoft JW, Oumouna M, Townsend HG, Gomis S, Babiuk LA, van Drunen Littel-van den Hurk S. Formulation with CpG oligodeoxynucleotides increases cellular immunity and protection induced by vaccination of calves with formalin-inactivated bovine respiratory syncytial virus. Virology 2006; 353: 316-323.
96. Asahi-Ozaki Y, Itamura S, Ichinohe T, Strong P, Tamura S, Takahashi H, Sawa H, Moriyama M, Tashiro M, Sara T, Kurata T, Hasegawa H. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes. Infect. 2006; 8: 2706-2714.
97. Carrington AC, Secombes CJ. A review of CpGs and their relevance to aquaculture. Vet. Immunol. Immunopathol. 2006; 112: 87-101.
98. Gluck R, Burri KG, Metcalfe I. Adjuvant and antigen delivery properties of virosomes. Curr. Drug Deliv. 2005; 2: 395-400.
99. Pascual DM, Morales RD, Gil ED, Munoz LM, Lopez JE, Casanueva OL. Adjuvants: present regulatory challenges. Vaccine 2006; 24 (2): S2-S9.
100. Dzierzbicka K, Kolodziejczyk AM. [Adjuvants-essential components of new generation vaccines]. Postepy Biochem. 2006; 52: 204-211.
101. Beignon AS, Brown F, Eftekhari P, Kramer E, Briand JP, Muller S, Partidos CD. A peptide vaccine administered transcutaneously together with cholera toxin elicits potent neutralising anti-FMDV antibody responses. Vet. Immunol. Immunopathol. 2005; 104: 273-280.
102. Egan MA, Chong SY, Hagen M, Megati S, Schadeck EB, Piacente P, Ma BJ, Montefiori DC, Haynes BF, Israel ZR, Eldridge JH, Staats HF. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. Vaccine 2004; 22: 3774-3788.
103. Fiorentini S, Marini E, Bozzo L, Trainini L, Saadoune L, Avolio M, Pontillo A, Bonfanti C, Sarmientos P, Caruso A. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH. Biopolymers 2004; 76: 334-343.
104. Head E, Barrett EG, Murphy MP, Das P, Nistor M, Sarsoza F, Glabe CC, Kayed R, Milton S, Vasilevko V, Milgram NW, Agadjanyan MG, Cribbs DH, Cotman CW. Immunization with fibrillar Abeta(1-42) in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Abeta. Vaccine 2006; 24: 2824-2834.
105. Audran R, Cachat M, Lurati F, Soe S, Leroy O, Corradin G, Druilhe P, Spertini F. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect. Immun. 2005; 73: 8017-8026.
106. Morita S, Oka Y, Tsuboi A, Kawakami M, Maruno M, Izumoto S, Osaki T, Taguchi T, Ueda T, Myoui A, Nishida S, Shirakata T, Ohno S, Oji Y, Aozasa K, Hatazawa J, Udaka K, Yoshikawa H, Yoshimine T, Noguchi S, Kawase I, Nakatsuka S, Sugiyama H, Sakamoto J. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn. J. Clin. Oncol. 2006; 36: 231-236.
107. Petrovsky N. Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine 2006; 24(Suppl 2): S2-S9.
108. Stills HF Jr. Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR. J. 2005; 46: 280-293.
109. Rosenthal KS, Zimmerman DH. Vaccines: all things considered. Clin. Vaccine Immunol. 2006; 13: 821-829.
110. Kirkley JE, Goldstein AL, Naylor PH. Adjuvant properties of montanide CSA 720 with a recombinant HIV P17 gag protein and synthetic peptide antigens. Scand. J. Immunol. 1996; 43: 431-438.
111. Westerfeld N, Zurbriggen R. Peptides delivered by immunostimulating reconstituted influenza virosomes. J. Pept. Sci. 2005; 11: 707-712.
112. Baldridge JR, McGowan P, Evans JT, Cluff C, Mossman S, Johnson D, Persing D. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert. Opin. Biol. Ther. 2004; 4: 1129-1138.
113. Bevaart L, Jansen MJ, van Vugt MJ, Verbeek JS, van de Winkel JG, Leusen JH. The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res. 2006; 66: 1261-1264.
114. Mata E, Carcaboso AM, Hernandez RM, Igartua M, Corradin G, Pedraz JL. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice. Vaccine 2007; 25: 877-885.
115. Rajkannan R, Dhanaraju MD, Gopinath D, Selvaraj D, Jayakumar R. Development of hepatitis B oral vaccine using B-cell epitope loaded PLG microparticles. Vaccine 2006; 24: 5149-5157.
116. Jaganathan KS, Vyas SP. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 2006; 24: 4201-4211.
117. Lord MJ, Jolliffe NA, Marsden CJ, Pateman CS, Smith DC, Spooner RA, Watson PD, Roberts LM. Ricin. Mechanisms of cytotoxicity. Toxicol. Rev. 2003; 22: 53-64.
118. Tobery TW, Siliciano RF. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J. Exp. Med. 1997; 185: 909-920.
119. Rodriguez F, Whitton JL. Enhancing DNA immunization. Virology 2000; 268: 233-238.
120. Kurts C, Heath WR, Carbone FR, Kosaka H, Miller JF. Cross-presentation of self antigens to CD8+ T cells: the balance between tolerance and autoimmunity. Novartis Found. Symp. 1998; 215: 172-181.
121. Humrich J, Jenne L. Viral vectors for dendritic cell-based immunotherapy. Curr. Top. Microbiol. Immunol. 2003; 276: 241-259.
122. Stefanova I, Dorfman JR, Germain RN. Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature 2002; 420: 429-434.
123. Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKall-Faienza K, Odermatt B, Hanahan D, Zinkernagel RM, Ohashi PS. Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 1997; 186: 645-653.
124. Jonuleit H, Schmitt E, Steinbrink K, Enk AH. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol. 2001; 22: 394-400.
125. Taams LS, Vukmanovic-Stejic M, Smith J, Dunne PJ, Fletcher JM, Plunkett FJ, Ebeling SB, Lombardi G, Rustin MH, Bijlsma JW, Lafeber FP, Salmon M, Akbar AN. Antigen-specific T cell suppression by human CD4+CD25+ regulatory T cells. Eur. J. Immunol. 2002; 32: 1621-1630.
126. Nickoloff BJ, Turka LA. Immunological functions of non-professional antigen-presenting cells: new insights from studies of T-cell interactions with keratinocytes. Immunol. Today 1994; 15: 464-469.
127. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, Garsky VM, Ionescu R, Rippeon Y, Shi L, Chastain MA, Condra JH, Davies ME, Liao J, Emini EA, Shiver JW. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004; 22: 2993-3003.
128. Tine JA, Firat H, Payne A, Russo G, Davis SW, Tartaglia J, Lemonnier FA, Demoyen PL, Moingeon P. Enhanced multiepitope-based vaccines elicit CDS+ cytotoxic T cells against both immunodominant and cryptic epitopes. Vaccine 2005; 23: 1085-1091.
129. Ho O, Green WR. Alternative translational products and cryptic T cell epitopes: expecting the unexpected. J. Immunol. 2006; 177: 8283-8289.
130. Cardinaud S, Moris A, Fevrier M, Rohrlich PS, Weiss L, Langlade-Demoyen P, Lemonnier FA, Schwartz O, Habel A. Identification of cryptic MHC I-restricted epitopes encoded by HIV-1 alternative reading frames. J. Exp. Med. 2004; 199: 1053-1063.
131. Lopez JA, Weilenman C, Audran R, Roggero MA, Bonelo A, Tiercy JM, Spertini F, Corradin G. A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategies. Eur. J. Immunol. 2001; 31: 1989-1998.
132. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 8809-8814.
133. van der Burg SH, Bijker MS, Welters MJ, Offringa R, Melief CJ. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Adv. Drug Deliv. Rev. 2006; 58: 916-930.
134. Slansky JE, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, Schneck JP, Margulies DH, Pardoll DM. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex, Immunity 2000; 13: 529-538.
135. Hertz CJ, Kiertscher SM, Godowski PJ, Bouis DA, Norgard MV, Roth MD, Modlin RL. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J. Immunol. 2001; 166: 2444-2450.
136. Duesberg U, von dem BA, Kirschning C, Miyake K, Sauerbruch T, Spengler U. Cell activation by synthetic lipopeptides of the hepatitis C virus (HCV)-core protein is mediated by toll like receptors (TLRs) 2 and 4. Immunol. Lett. 2002; 84: 89-95.
137. Langhans B, Schweitzer S, Nischalke HD, Braunschweiger I, Sauerbruch T, Spengler U. Hepatitis C virus-derived lipopeptides differentially induce epitope-specific immune responses in vitro. J. Infect. Dis. 2004; 189: 248-253.
138. Jackson DC, Lau YF, Le T, Suhrbier A. Deliyannis G, Cheers C, Smith C, Zeng W, Brown LE. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 15440-15445.
139. Espuelas S, Roth A, Thumann C, Frisch B, Schuber F. Effect of synthetic lipopeptides formulated in liposomes on the maturation of human dendritic cells. Mol. Immunol. 2005; 42: 721-729.
140. Kang TH, Lee JH, Bae HC, Noh KH, Kim JH, Song CK, Shin BC, Hung CF, Wu TC, Park JS, Kim TW. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments. Immunol. Lett. 2006; 106: 126-134.
141. Moris A, Nobile C, Buseyne F, Porrot F, Abastado JP, Schwartz O. DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation. Blood 2004; 103: 2648-2654.
142. Johansen P, Haffner AC, Koch F, Zepter K, Erdmann I, Maloy K, Simard JJ, Storni T, Senti G, Bot A, Wuthrich B, Kundig TM. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur. J. Immunol. 2005; 35: 568-574.
143. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, Yuan L, Chisari FV, Furze J, Bartholomeuz R. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I, Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 1995; 95: 341-349.
144. Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J, Scheinberg DA. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000; 95: 1781-1787.
145. Fiers W, De Filette M, Birkett A, Neirynck S, Min JW. A "universal" human influenza A vaccine. Virus Res. 2004; 103: 173-176.
146. Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science 1988; 242: 1171-1173.
147. Ji JP, Loeb LA. Fidelity of HIV-1 reverse transcriptase copying RNA in vitro. Biochemistry 1992; 31: 954-958.
148. Carruth LM, Greten TF, Murray CE, Castro MG, Crone SN, Pavlat W, Schneck JP, Siliciano RF. An algorithm for evaluating human cytotoxic T lymphocyte responses to candidate AIDS vaccines. AIDS Res. Hum. Retroviruses 1999; 15: 1021-1034.
149. Niedrig M, Gregersen JP, Fultz PN, Broker M, Mehdi S, Hilfenhaus J. Immune response of chimpanzees after immunization with the inactivated whole immunodeficiency virus (HIV-1), three different adjuvants and challenge. Vaccine 1993; 11: 67-74.
150. Nabel GJ. HIV vaccine strategies. Vaccine 2002; 20:1945-1947.
151. Yasutomi Y, Palker TJ, Gardner MB, Haynes BF, Letvin NL. Synthetic peptide in mineral oil adjuvant elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes in rhesus monkeys. J. Immunol. 1993; 151: 5096-5105.
152. Letvin NL, Mascola JR. Sun Y, Gorgone DA, Buzby AP, Xu L, Yang ZY, Chakrabarti B, Rao SS, Schmitz JE, Montefiori DC, Barker BR, Bookstein FL, Nabel GJ. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006; 312: 1530-1533.
153. Cristillo AD, Wang S, Caskey MS, Unangst T, Hocker L, He L, Hudacik L, Whitney S, Keen T, Chou TH, Shen S, Joshi S, Kalyanaraman VS, Nair B, Markham P, Lu S, Pal R. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology 2006; 346: 151-168.
154. Azizi A, Ghorbani M, Soare C, Mojibian M, Diaz-Mitoma F. Synergistic effect of combined HIV/HCV immunogens: a combined HIV-1/HCV candidate vaccine induces a higher level of CD8+ T cell-immune responses in HLA-A2.1 mice. Curr. HIV. Res. 2007; 5: 211-219.
155. Azizi A, Ghorbani M, Kryworuchko M, Aucoin S, Diaz-Mitoma F. Potency of cell-mediated immune responses to different combined HIV-1 immunogens in a humanized murine model. Hum. Vaccin. 2005; 1: 170-176.
156. Cann AJ, Stanway G, Hughes PJ, Minor PD, Evans DM, Schild GC, Almond JW. Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Res. 1984; 12: 7787-7792.
157. Voltan R, Robert-Guroff M. Live recombinant vectors for AIDS vaccine development. Curr, Mol. Med. 2003; 3: 273-284.
158. Bermudez A, Reyes C, Guzman F, Vanegas M, Rosas J, Amador R, Rodriguez R, Patarroyo MA, Patarroyo ME, Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterizatton. Vaccine 2007.
159. Calvo-Calle JM, Oliveira GA, Nardin EH. Human CD4+ T cells induced by synthetic peptide malaria vaccine are comparable to cells elicited by attenuated Plasmodium falciparum sporozoites. J. Immunol. 2005; 175: 7575-7585.
160. Jiang S, Song R, Popov S, Mirshahidi S, Ruprecht RM. Overlapping synthetic peptides as vaccines, Vaccine 2006; 24: 6356-6365.
161. Purcell AW, Zeng W, Mifsud NA, Ely LK, Macdonald WA, Jackson DC. Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design. J. Pept. Sci. 2003; 9: 255-281.